Blue Owl Capital Holdings LP reported 50 positions worth $642.51M for the quarter ended Jun 30, 2026, up 80.2% on the prior quarter. It opened 11 new positions, added to 11, trimmed 13 and exited 6. Its largest holding is Space Exploration Technologies Corp at 37.2% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| SPCX Space Exploration Technologies Corp | +1.40M | – | $239.00M | 37.2% |
| COF Capital One Financial Corp | +119.8K | – | $24.03M | 3.74% |
| ARTV Artiva Biotherapeutics, Inc. | +874.5K | – | $8.48M | 1.32% |
| DELL Dell Technologies Inc. | +19.1K | +137.1% | $8.22M | 2.21% |
| SGMT Sagimet Biosciences Inc. | +926.7K | +277.5% | $7.16M | 1.52% |
| CMPS COMPASS Pathways plc | +450.0K | – | $6.37M | 0.991% |
| LRMR Larimar Therapeutics, Inc. | +2.04M | +28.7% | $6.23M | 4.35% |
| VRDN Viridian Therapeutics, Inc.\DE | +260.0K | – | $4.78M | 0.743% |
| ORIC Oric Pharmaceuticals, Inc. | +250.0K | +166.7% | $2.71M | 0.674% |
| CABA Cabaletta Bio, Inc. | +714.7K | – | $2.22M | 0.346% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| ENGN enGene Therapeutics Inc. | -4.42M | -100.0% | $30.08M | Exited |
| MPLT MapLight Therapeutics, Inc. | -276.0K | -27.4% | $9.89M | 4.07% |
| CGEM Cullinan Therapeutics, Inc. | -370.0K | -19.4% | $6.74M | 4.36% |
| CVEO Civeo Corp | -180.5K | -100.0% | $4.78M | Exited |
| OVID Ovid Therapeutics Inc. | -1.90M | -100.0% | $4.23M | Exited |
| RARE Ultragenyx Pharmaceutical Inc. | -120.0K | -39.7% | $4.01M | 0.949% |
| PLRX Pliant Therapeutics, Inc. | -2.97M | -100.0% | $3.74M | Exited |
| ELDN Eledon Pharmaceuticals, Inc. | -853.4K | -60.1% | $3.36M | 0.347% |
| AKTS Aktis Oncology, Inc. | -91.1K | -2.9% | $2.94M | 15.4% |
| EYPT EyePoint, Inc. | -150.0K | -16.4% | $2.14M | 1.7% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| SPCX Space Exploration Technologies Corp | +1.40M | $239.00M | 37.2% |
| COF Capital One Financial Corp | +119.8K | $24.03M | 3.74% |
| ARTV Artiva Biotherapeutics, Inc. | +874.5K | $8.48M | 1.32% |
| CMPS COMPASS Pathways plc | +450.0K | $6.37M | 0.991% |
| VRDN Viridian Therapeutics, Inc.\DE | +260.0K | $4.78M | 0.743% |
| CABA Cabaletta Bio, Inc. | +714.7K | $2.22M | 0.346% |
| CHYM Chime Financial, Inc. | +89.9K | $1.84M | 0.286% |
| HELP Helus Pharma Inc. | +59.9K | $396.01K | 0.062% |
| CELC Celcuity Inc. | +1,249 | $130.67K | 0.02% |
| VOD Vodafone Group Public Ltd Co | +5,371 | $71.01K | 0.011% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| ENGN enGene Therapeutics Inc. | -4.42M | $30.08M | 8.43% |
| CVEO Civeo Corp | -180.5K | $4.78M | 1.34% |
| OVID Ovid Therapeutics Inc. | -1.90M | $4.23M | 1.19% |
| PLRX Pliant Therapeutics, Inc. | -2.97M | $3.74M | 1.05% |
| EPD Enterprise Products Partners L.P. | -31.3K | $1.18M | 0.332% |
| CAH Cardinal Health Inc | -1,718 | $363.03K | 0.102% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | SPCX Space Exploration Technologies Corp | Industrials | 1.40M | $239.00M | 37.2% | +1.40M | – | New | 0.01% |
| 2 | AKTS Aktis Oncology, Inc. | Healthcare | 3.07M | $98.95M | 15.4% | -91.1K | -2.9% | Reduced | 5.55% |
| 3 | CGEM Cullinan Therapeutics, Inc. | Healthcare | 1.54M | $28.04M | 4.36% | -370.0K | -19.4% | Reduced | 2.39% |
| 4 | LRMR Larimar Therapeutics, Inc. | Healthcare | 9.16M | $27.95M | 4.35% | +2.04M | +28.7% | Added | 8.82% |
| 5 | NCDL Nuveen Churchill Direct Lending Corp. | Financial Services | 2.14M | $26.62M | 4.14% | 0 | 0.0% | Unchanged | 4.34% |
| 6 | MPLT MapLight Therapeutics, Inc. | Healthcare | 729.9K | $26.16M | 4.07% | -276.0K | -27.4% | Reduced | 1.61% |
| 7 | COF Capital One Financial Corp | Financial Services | 119.8K | $24.03M | 3.74% | +119.8K | – | New | 0.02% |
| 8 | OBDC Blue Owl Capital Corp | Financial Services | 2.05M | $22.23M | 3.46% | 0 | 0.0% | Unchanged | 0.41% |
| 9 | DELL Dell Technologies Inc. | Technology | 33.0K | $14.22M | 2.21% | +19.1K | +137.1% | Added | 0.01% |
| 10 | HLLY Holley Inc. | Consumer Discretionary | 4.38M | $11.16M | 1.74% | +140.0K | +3.3% | Added | 3.64% |
| 11 | EYPT EyePoint, Inc. | Healthcare | 762.6K | $10.91M | 1.7% | -150.0K | -16.4% | Reduced | 0.88% |
| 12 | SGMT Sagimet Biosciences Inc. | Healthcare | 1.26M | $9.74M | 1.52% | +926.7K | +277.5% | Added | 2.04% |
| 13 | CRVS Corvus Pharmaceuticals, Inc. | Healthcare | 608.6K | $9.09M | 1.42% | +63.6K | +11.7% | Added | 0.66% |
| 14 | ARTV Artiva Biotherapeutics, Inc. | Healthcare | 874.5K | $8.48M | 1.32% | +874.5K | – | New | 1.79% |
| 15 | CMPX Compass Therapeutics, Inc. | Healthcare | 3.62M | $7.94M | 1.24% | +682.6K | +23.2% | Added | 1.94% |
Tip. Select a row to see that position’s full history at Blue Owl Capital Holdings.
As of its Q2 2026 13F filing, Blue Owl Capital Holdings LP’s five largest positions were Space Exploration Technologies Corp (SPCX) at 37.2%, Aktis Oncology, Inc. (AKTS) at 15.4%, Cullinan Therapeutics, Inc. (CGEM) at 4.4%, Larimar Therapeutics, Inc. (LRMR) at 4.4%, Nuveen Churchill Direct Lending Corp. (NCDL) at 4.1% of the reported portfolio.
Blue Owl Capital Holdings LP reported a 13F portfolio worth $642.51M across 50 positions for Q2 2026. That is up 80.2% from the previous quarter.
Its largest purchases by value were Space Exploration Technologies Corp ($239.00M), Capital One Financial Corp ($24.03M), Artiva Biotherapeutics, Inc. ($8.48M). It opened 11 new positions.
Its largest sales by value were enGene Therapeutics Inc. ($30.08M), MapLight Therapeutics, Inc. ($9.89M), Cullinan Therapeutics, Inc. ($6.74M). It exited 6 positions entirely.
From the Form 13F-HR reports Blue Owl Capital Holdings LP files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.